News
02-08-2015, 04:22 AM
Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.
More... (http://www.news-medical.net/news/20150208/Helsinn-begins-elsiglutide-Phase-IIB-trial-for-prevention-of-chemotherapy-induced-diarrhea.aspx)
More... (http://www.news-medical.net/news/20150208/Helsinn-begins-elsiglutide-Phase-IIB-trial-for-prevention-of-chemotherapy-induced-diarrhea.aspx)